Certara Reports First Quarter 2025 Financial Results Blog Post
Reiterates Full Year 2025 Financial Guidance RADNOR, PA— 2025年5月5日-- Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in model-informed drug development, today reported its financial results for the first quarter...
Essentials of Model-informed Drug Development in Oncology Blog Post
Model-informed drug development in oncology is critical to developing safer and more effective cancer drugs. Read the blog to learn more…
SEND V4.0 – What to Expect and When to Expect It Blog Post
Peggy Zorn 2025年4月24日 As the Standard for Exchange of Nonclinical Data (SEND) continues to evolve in both scope and complexity, the upcoming release of SEND 4.0 marks a...
NAM Strategies Page
Tailored NAM strategies to reduce animal use, support global regulatory alignment, and accelerate your drug development program with expert guidance.
Managing Clinical Metadata for your Vendors, Studies, and Datasets Blog Post
Erin Erginer Kristin Kelly Gilbert Hunter 2025年4月21日 Clinical research is witnessing an evolution, driven by the increasing complexities of modern trials, rising data volumes, and the need for...
Enabling Personalized Therapy with PBPK Modeling for Pediatric Epilepsy Blog Post
Our partner GRIN Therapeutics, Inc., an affiliate of Neurvati Neurosciences, focuses on the research and development of precision therapeutics for pediatric neurodevelopmental disorders. GRIN-related disorders, first classified in 2010, are...
How to Use Fix Tips for Better Clinical Data Issue Management Blog Post
Julie Ann Hood Principal Consultant 2025年4月15日 Clinical data issue management: the basics Prior to submission to any regulatory agency, standardized study data is evaluated using at least one validation tool to ensure...
PharmaSUG 2025 Blog Post
[event_date_range] – [acf field="event_location"] – Booth [acf field="event_booth"]
